Detalhe da pesquisa
1.
Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Diabetic Kidney Disease: The CREDENCE Trial.
Circulation
; 148(8): 651-660, 2023 08 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-37603600
2.
Vascular endothelial growth factors and risk of cardio-renal events: Results from the CREDENCE trial.
Am Heart J
; 271: 38-47, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38401646
3.
Natriuretic Peptides and Prognosis in Patients With Type 2 Diabetes Mellitus and High Risk for Cardiovascular Events.
J Card Fail
; 2024 Apr 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38614444
4.
Tailored Chemical Reactivity Probes for Systemic Imaging of Aldehydes in Fibroproliferative Diseases.
J Am Chem Soc
; 145(38): 20825-20836, 2023 09 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-37589185
5.
Sodium glucose co-transporter 2 inhibition increases epidermal growth factor expression and improves outcomes in patients with type 2 diabetes.
Kidney Int
; 104(4): 828-839, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37543256
6.
Insulin growth factor axis and cardio-renal risk in diabetic kidney disease: an analysis from the CREDENCE trial.
Cardiovasc Diabetol
; 22(1): 176, 2023 07 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37438734
7.
Derivation and independent validation of kidneyintelX.dkd: A prognostic test for the assessment of diabetic kidney disease progression.
Diabetes Obes Metab
; 25(12): 3779-3787, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37722962
8.
Liver function markers predict cardiovascular and renal outcomes in the CANVAS Program.
Cardiovasc Diabetol
; 21(1): 127, 2022 07 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35787704
9.
Endotrophin is a risk marker of complications in CANagliflozin cardioVascular Assessment Study (CANVAS): a randomized controlled trial.
Cardiovasc Diabetol
; 21(1): 261, 2022 11 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-36443792
10.
Clinical Utility of KidneyIntelX in Early Stages of Diabetic Kidney Disease in the CANVAS Trial.
Am J Nephrol
; 53(1): 21-31, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35016188
11.
Mechanisms of action of the sodium-glucose cotransporter-2 (SGLT2) inhibitor canagliflozin on tubular inflammation and damage: A post hoc mediation analysis of the CANVAS trial.
Diabetes Obes Metab
; 24(10): 1950-1956, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35635326
12.
Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial.
Diabetologia
; 64(10): 2147-2158, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34415356
13.
Replication and cross-validation of type 2 diabetes subtypes based on clinical variables: an IMI-RHAPSODY study.
Diabetologia
; 64(9): 1982-1989, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34110439
14.
Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease.
Diabetologia
; 62(7): 1154-1166, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31001673
15.
Association of diabetes-related kidney disease with cardiovascular and non-cardiovascular outcomes: a retrospective cohort study.
BMC Endocr Disord
; 19(1): 89, 2019 Aug 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-31455289
16.
Metabolic tracing of monoacylglycerol acyltransferase-2 activity in vitro and in vivo.
Anal Biochem
; 524: 68-75, 2017 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27665677
17.
Role of Glycosuria in SGLT2 Inhibitor-Induced Cardiorenal Protection: A Mechanistic Analysis of the CREDENCE Trial.
Diabetes
; 73(2): 250-259, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37939214
18.
Associations of Angiopoietin 2 and Vascular Endothelial Growth Factor-A Concentrations with Clinical End Points.
Clin J Am Soc Nephrol
; 19(4): 429-437, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38099944
19.
Autoantibodies to Erythropoietin Receptor and Clinical Outcomes in Patients With Type 2 Diabetes and CKD: A Post Hoc Analysis of CREDENCE Trial.
Kidney Int Rep
; 9(2): 347-355, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38344715
20.
Multi-omics subgroups associated with glycaemic deterioration in type 2 diabetes: an IMI-RHAPSODY Study.
Front Endocrinol (Lausanne)
; 15: 1350796, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38510703